Skip to main content
Photocure ASA logo

Photocure ASA — Investor Relations & Filings

Ticker · PHO ISIN · NO0010000045 LEI · 5967007LIEEXZXG8OW35 OL Manufacturing
Open in API
Filings indexed 1,320 across all filing types
Latest filing 2022-07-27 Regulatory Filings
Country NO Norway
Listing OL PHO

About Photocure ASA

https://www.photocure.com/

Photocure is a specialty pharmaceutical company focused on bladder cancer. It develops and commercializes products and medical devices based on proprietary photodynamic technology. The company's primary offering is Blue Light Cystoscopy (BLC) with its imaging agents, Hexvix®/Cysview®, which is used for the improved detection and management of bladder cancer. Photocure aims to deliver transformative solutions to the urologic oncology community to improve patient outcomes. The company is also engaged in developing advanced diagnostic technologies, including the integration of artificial intelligence with its BLC systems.

Recent filings

Filing Released Lang Actions
Photocure Provides Update on Anticipated Commercial Availability of Karl Storz's New Blue Light System in the United States
Regulatory Filings Classification · 95% confidence The document is a press release dated July 27, 2022, providing an update on the anticipated commercial availability of a product (Karl Storz's new Blue Light System) and discussing operational progress (installation of BLC towers, market penetration). It contains forward-looking statements and general company/product information, typical of an announcement intended for investors and the public regarding business operations and timelines. It is not a formal regulatory filing like a 10-K, a detailed financial report (IR), a transcript (CT), or a specific governance document (DEF 14A, CGR). Since it is an announcement updating stakeholders on business progress and timelines, it best fits the general 'Regulatory Filings' (RNS) category as a broad press release, or potentially an 'Earnings Release' (ER) if it were tied to a specific reporting period's results, but here it is focused on a product launch delay. Given the nature of updating on operational/commercial timelines outside of formal earnings, RNS is the most appropriate general category for a non-specific press release.
2022-07-27 English
Photocure Provides Update on Anticipated Commercial Availability of Karl Storz's New Blue Light System in the United States
Regulatory Filings Classification · 100% confidence The document is a press release from Photocure ASA dated July 27, 2022, providing an update on the delayed commercial availability of a product due to supply chain issues. It discusses operational updates, market penetration, and includes standard forward-looking statements and boilerplate information about the company and the disease area. This type of announcement, which communicates significant business or operational news outside of mandated periodic financial filings (like 10-K or IR), is typically classified as a general regulatory announcement or press release. Since it is not a formal Earnings Release (ER), a Capital/Financing Update (CAP), or a specific legal/director filing, the most appropriate general category for a corporate update of this nature, especially one that might be filed with a regulatory body like the Oslo Stock Exchange, is Regulatory Filings (RNS). It is not short enough to be purely an RPA, as it contains substantial operational detail.
2022-07-27 English
Photocure ASA – Share option grant
Director's Dealing Classification · 100% confidence The document text consists of structured tables detailing transactions involving 'person discharging managerial responsibilities' (insiders) at 'PHOTOCURE ASA'. Specifically, it reports the 'Grant of share options' to executives like the CEO and CFO. This type of mandatory disclosure regarding personal share transactions by directors and executives is classified as Director's Dealing.
2022-07-20 English
Photocure ASA – Share option grant
Remuneration Information Classification · 99% confidence The document announces the grant of share options to employees and board members, detailing the number of options, exercise price, and listing specific primary insiders who received grants. This activity directly relates to insider transactions and executive/director compensation/incentives. While it involves management (MANG) and remuneration (DEF 14A), the core subject is the transaction of shares by insiders (directors and executives). The text explicitly mentions 'Primary insider notifications pursuant to the market abuse regulation article 19 are attached.' Regulation Article 19 filings specifically cover transactions by persons discharging managerial responsibilities (PDMRs), which aligns perfectly with Director's Dealing (DIRS). Since the document details the specific options granted to directors and executives, DIRS is the most precise classification.
2022-07-20 English
Photocure Collaborations at EAU Support the Latest Advancements in Bladder Cancer Technology
Regulatory Filings Classification · 95% confidence The document is explicitly titled as a "Press release" and details company activities, product showcases (Hexvix®/Cysview®), and collaborations presented at a medical congress (EAU Congress) in July 2022. It contains forward-looking statements, quotes from management, and general company information, which are characteristic features of a press release announcing business developments. Since there is no indication this is a formal regulatory filing like a 10-K, an earnings release (ER), or a report itself (like AR or IR), and it is a general announcement of corporate news, the most appropriate classification is Regulatory Filings (RNS), which serves as a general category for non-standard, yet important, public announcements not covered by more specific codes. It is not an announcement of a report publication (RPA) because it is the content itself, not just a notice that content is available.
2022-07-05 English
Photocure Collaborations at EAU Support the Latest Advancements in Bladder Cancer Technology
Earnings Release Classification · 99% confidence The document is explicitly labeled as a 'Press release' dated July 5, 2022. It discusses company activities, collaborations (with Karl Storz, Richard Wolf), product demonstrations at a medical congress (EAU), and includes quotes from management (VP, GM, CEO, CFO contacts). This format—a news announcement detailing recent business developments, partnerships, and product showcases—is characteristic of an Earnings Release (ER) or a general corporate announcement. Since it is not a formal regulatory filing like a 10-K, nor a transcript (CT), nor a specific financial report (IR, AR), it fits best as an Earnings Release (ER) if it accompanied quarterly results, or a general Regulatory Filing (RNS) if it's purely operational news. Given the context of a press release detailing recent operational achievements and product advancements, and lacking explicit quarterly financial tables, it leans towards a general corporate announcement. However, many companies issue press releases covering operational highlights around earnings periods. Since it is a formal announcement of news, and not a specific report like an IR or 10-K, and it's not a proxy/voting document, the most appropriate classification among the specific options is ER (Earnings Release, often used broadly for major news announcements) or RNS (Regulatory Filings, as a fallback). Given the content is focused on technology advancements and congress participation rather than financial performance highlights, RNS is a safer general classification for non-standard news releases, but ER is often used for press releases issued by public companies. Since it is a press release announcing business updates, and not a specific financial report, I will classify it as RNS as it is a general regulatory/corporate announcement that doesn't fit the other specific categories like DIV, CAP, or ER (which usually contains key financial metrics). Q3 2022
2022-07-05 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.